TIDMFARN

RNS Number : 6853X

Faron Pharmaceuticals Oy

22 December 2023

Faron Pharmaceuticals Oy

("Faron" or "Company")

Faron's Financial Calendar for 202 4

Company announcement

TURKU, FINLAND / BOSTON, MA - December 22, 2023 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on tackling difficult-to-treat cancers and inflammation via precision immunotherapy, today announces the following dates for the Company's financial reporting in 202 4 :

 
 February   Financial statement release for the full year 202 3 and 
  2 9        Annual Report 202 3 including financial statements for 
             the full year 
 August 2   Half-year financial report for the period January 1 to 
  7          June 30, 202 4

The annual general meeting is planned to be held on March 2 2 , 202 4 . A separate stock exchange notice will be issued by Faron's Board of Directors to convene the meeting.

For more information please contact:

Investor Contact

LifeSci Advisors

Daniel Ferry

Managing Director

daniel@lifesciadvisors.com

+1 (617) 430-7576

ICR Consilium

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: Faron@consilium-comms.com

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments treatments and as a monotherapy in last line solid cancers . Further information is available at www.faron.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDUAABRONUUUAA

(END) Dow Jones Newswires

December 22, 2023 02:00 ET (07:00 GMT)

Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Faron Pharmaceuticals Oy Charts.
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Faron Pharmaceuticals Oy Charts.